Home / Treatment Library / Tirzepatide for Medical Weight Management
Dual-action therapy with medical oversight. A clear, evidence-aware guide to candidacy, treatment, recovery, limitations and next steps.
Physician-led guidance brings your goals, health history and realistic expectations into one thoughtful plan.
Tirzepatide activates GIP and GLP-1 receptors. FDA-approved Zepbound is indicated for chronic weight management in eligible adults, with additional labeled use for moderate-to-severe obstructive sleep apnea in adults with obesity, alongside nutrition and physical activity.
Eligibility depends on current labeling, BMI, related conditions, medications and risk profile. The prescriber confirms the indication, coordinates diabetes medicines and assesses gastrointestinal, gallbladder and thyroid history.
Tirzepatide is contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2 and with serious hypersensitivity. Pregnancy and important gastrointestinal, pancreatic, gallbladder, kidney, eye and medication issues require review.
These are practical planning ranges, not promises. Your consultation determines the exact plan.
The clinician reviews weight history, health conditions, medications, pregnancy plans and labs.
If eligible, Zepbound or another appropriate FDA-approved product is prescribed and titrated according to labeling and tolerability.
Weight, nutrition, strength, adverse effects and related conditions are monitored. The plan changes when benefit, risk or access changes.
Common effects include nausea, diarrhea, vomiting, constipation, abdominal discomfort and injection-site reactions. Important risks include pancreatitis, gallbladder disease, dehydration-related kidney injury, severe gastrointestinal effects, allergy and low blood sugar with certain diabetes drugs. Labeling includes a boxed thyroid C-cell tumor warning.
Safe care requires more than escalating a dose. Experienced supervision verifies sourcing, coordinates diabetes or sleep-apnea treatment, protects nutrition and lean mass, and recognizes when side effects or inadequate benefit require a change.
Consultations and follow-up may be in-office or by telehealth for patients physically located in Texas, North Carolina or South Carolina, subject to eligibility and law. Labs or in-person assessment may be required.
Pricing: Consultation required. Medication cost varies by product, insurance, pharmacy and dose. Coverage and availability cannot be guaranteed.
When a prescription or compounded preparation is clinically appropriate, the dispensing pharmacy, facility classification and current license status matter. Compounded medications are not FDA-approved drug products.
Medical-content evidence review: September 3, 2026. Content is written for patient education and structured from current primary regulatory, labeling and professional sources. It has not been individualized to your medical history. Product labeling and guidance can change; a licensed Identity Aesthetics provider confirms current suitability, informed consent and treatment details before care.
Bring your goals, questions, medication list and prior treatment history. We will help you decide whether Tirzepatide for Medical Weight Management—or an alternative—makes sense.
